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A new World Health Organization (WHO) Classiﬁcation of
Tumors of the Pleura has recently been published. While
the histologic classiﬁcation of pleural malignant meso-
thelioma remains the same in the 2015 WHO classiﬁcation
as it was in the 2004 classiﬁcation, multiple new obser-
vations have been recorded. First, more detailed study has
been performed of histologic subtyping of epithelioid
mesothelioma. In particular, it has been recognized that
the pleomorphic subtype is associated with a poor prog-
nosis, similar to that of sarcomatoid malignant mesothe-
lioma. Second, there is improved understanding of the role
of immunohistochemistry in distinguishing mesothelioma
from carcinomas of various sites. Third, the criteria for
distinguishing malignant mesothelioma from reactive
mesothelial proliferations has been further reﬁned.
Fourth, additional studies of sarcomatoid mesothelioma
have deﬁned the frequency and spectrum of various his-
tologic and immunohistochemical features, including
heterologous elements. Finally, pleural well-differentiated
papillary mesotheliomas are better deﬁned and cases with
invasive foci are recognized. In addition, several prom-
ising observations in mesothelioma pathology and ge-
netics have been made in the past decade. These are now
the subject of further investigation to determine if they
can be validated in ways that will signiﬁcantly impact
clinical practice. These include a preliminary study of
grading, suggesting that nuclear atypia and mitotic count
are independent prognostic markers. The discovery of
inactivating mutations in the BRCA1-associated protein 1
gene in sporadic and hereditary mesothelioma has opened
up a variety of novel molecular, clinical, and diagnostic
investigations. One possible diagnostic application
includes the setting of separating mesothelioma fromJournal of Thoracic Oncology Vol. 11 No. 2: 142-154reactive mesothelial proliferations, where it may play a
role in conjunction with p16 FISH. Another useful dis-
covery was that the NAB2–STAT6 fusion is characteristic
of solitary ﬁbrous tumors. This led to development of a
STAT6 antibody that is a reliable immunohistochemical
marker for solitary ﬁbrous tumors. Genetic studies also
led to the ﬁnding that WWTR1–CAMTA1 fusions are useful
diagnostic markers for epithelioid hemangioendothelio-
mas, which can present as pleural-based masses. Finally,
desmoid type ﬁbromatosis, a locally aggressive tumor that
can present in the pleura, has been shown to frequently
have CTNNB1 gene mutations and express b-catenin by
immunohistochemistry.
 2015 International Association for the Study of Lung
Cancer. Published by Elsevier Inc. All rights reserved.
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The 2015 World Health Organization (WHO) Clas-
siﬁcation of Tumors of the Pleura has recently been
published.1,2 While the histologic classiﬁcation of ma-
lignant mesothelioma remains the same in the 2015
WHO classiﬁcation (Table 1) as it was in the 2004 WHO
classiﬁcation,3 multiple new observations have been
reported. Diffuse malignant mesothelioma (DMM)
needs to be distinguished from other mesotheliomas
that have a much better prognosis, including localized
malignant mesotheliomas (LMMs) and well-
differentiated papillary mesotheliomas (WDPMs). The
purpose of this article is to present the 2015 WHO
classiﬁcation of pleural tumors and to summarize some
of the advances since 2004 that impact the improved
diagnosis of pleural tumors.
Pleural Malignant Mesothelioma:
Signiﬁcant Advances
Histologic Subtyping of Epithelioid
Mesothelioma
Themajor histologic types of DMM, including epithelioid,
sarcomatoid, and biphasic, are well recognized, and patients
with sarcomatoid and biphasic tumors have signiﬁcantly
poorer survival compared to patients with epithelioid
DMMs.4,5 Within the category of pleural epithelioid
DMMs, while a variety of morphologic subtypes are
recognized—including tubulopapillary, papillary, micro-
papillary, trabecular, solid, and pleomorphic—there haveTable 1.World Health Organization Classiﬁcation of Tumors of
ICD-O Codea
Mesothelial tumors
Diffuse malignant mesothelioma
Epithelioid mesothelioma 9052/3
Sarcomatoid mesothelioma 9051/3
Desmoplastic mesothelioma 9051/3
Biphasic mesothelioma 9053/3
Localized malignant mesothelioma
Epithelioid mesothelioma 9052/3
Sarcomatoid mesothelioma 9051/3
Biphasic mesothelioma 9053/3
Well differentiated papillary mesothelioma 9052/1b
Adenomatoid tumor 9054/0
Lymphoproliferative disorders
Primary effusion lymphoma 9678/3
Diffuse large B-cell lymphoma associated with
chronic inﬂammation
9680/3
Adapted with permission from Travis et al.1
aMorphology codes are taken from the ICD-O.58 Behavior is coded /
behavior, /2 for carcinoma in situ and grade III intraepithelial neopla
bThis new code was approved by the International Agency for Resear
national Classiﬁcation of Diseases for Oncology.
ICD-O, International Classiﬁcation of Diseases for Oncology.been few comprehensive studies examining the prog-
nostic importance of these patterns. Several recent
studies have addressed this topic, revealing an aggres-
sive behavior of epithelioid DMMs with pleomorphic
features.6–8
Tumors with anaplastic or prominent giant cells,
often multinucleated, are designated pleomorphic
(Fig. 1A). Two studies demonstrated signiﬁcantly poorer
prognosis for the pleomorphic subtype of epithelioid
DMM compared to other epithelioid tumors, and survival
was similar to that of patients with biphasic and sarco-
matoid DMMs.6,8 While both papers proposed that the
pleomorphic pattern be reclassiﬁed from the epithelioid
to the sarcomatoid subtype, this was not accepted by the
WHO panel. According to the 2015 WHO classiﬁcation,
these tumors are regarded as a poor prognostic subset of
epithelioid DMMs. In addition, after excluding the pleo-
morphic tumors, Kadota et al.8 showed that the com-
bined group of tubulopapillary and trabecular tumors
had a more favorable prognosis than the solid subtype
and the combined solid/micropapillary group (Fig. 1B
and C). Brcic et al.6 also showed substantial interob-
server reproducibility among two observers in the his-
tologic subtyping of epithelioid DMMs. These ﬁndings
are promising in that histologic subtyping of epithelioid
DMMs may help to identify prognostic subsets and that
these may be reproducible. However, more data are
needed on this subject before histologic subtyping can be
formally introduced into the classiﬁcation of pleural
epithelioid DMMs.the Pleura
ICD-O Codea
Mesenchymal tumors
Epithelioid hemangioendothelioma 9133/3
Angiosarcoma 9120/3
Synovial sarcoma 9040/3
Solitary ﬁbrous tumor 8815/1
Malignant solitary ﬁbrous tumor 8815/3
Desmoid-type ﬁbromatosis 8821/1
Calcifying ﬁbrous tumor 8817/0
Desmoplastic round cell tumor 8806/3
0 for benign tumors, /1 for unspeciﬁed, borderline, or uncertain
sia, and /3 for malignant tumors.
ch on Cancer/World Health Organization Committee for the Inter-
Figure 1. Diffuse malignant mesothelioma, epithelioid type. (A) The pleomorphic pattern consists of large atypical and
multinucleated tumor cells, some with prominent nucleoli. (B) The solid pattern, with sheets of epithelioid tumor cells. (C)
The micropapillary pattern, with a nest of tumor cells growing in papillae lacking ﬁbrovascular cores. (Reprinted from Travis
et al.1, with permission from Dr. William D. Travis.) (D) Staining with calretinin shows positive nuclear and cytoplasmic
reactivity. (Reprinted from Travis et al.1, with permission from Dr. Francoise Galateau-Salle.)
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Mesothelioma Diagnosis
There is an improved understanding of the role of
immunohistochemistry in distinguishing malignant me-
sothelioma from carcinomas of various sites.9 In the
2004 WHO classiﬁcation, the discussion of immunohis-
tochemical markers to distinguish malignant mesotheli-
oma from carcinomas was limited to the general
carcinoma markers.3 However, in a subsequent guideline
from the International Mesothelioma Interest Group,9
more detail was provided on the recommended
workup for the separation of mesothelioma from various
carcinomas, including lung, breast, ovarian, colonic,
squamous cell, and renal cell carcinoma. Site-speciﬁc
carcinoma marker panels are introduced in the 2015
WHO classiﬁcation (Table 2). However, there are no site-
speciﬁc antibodies that are 100% speciﬁc and sensitive
for metastatic carcinomas from most organs; therefore,
panels of antibodies are recommended.
The most common circumstance in which immuno-
histochemistry provides an aid to the diagnosis of ma-
lignant mesothelioma is the separation of the epithelioid
variant of mesothelioma from other carcinomas that
might involve the pleura.9 The most common differential
diagnostic consideration in this regard is with primaryadenocarcinoma of the lung. Speciﬁcity and sensitivity
considerations support the use of calretinin (Fig. 1D),
cytokeratins 5/6, WT-1, and D2-40 as positive meso-
thelial markers, and carcinoembryonic antigen (CEA),
B72.3, Bg8, BerEP4, and MOC-31 as positive carcinoma
markers (Table 2).9 In this situation, the use of at least
two of these mesothelial markers and two of these car-
cinoma markers in addition to TTF-1 is recommended.
A number of organ-speciﬁc markers are also of use to
help exclude metastatic disease from certain primary
sites. These include TTF-1 and Napsin A for adenocar-
cinoma of the lung, PAX-8 for renal cell and thyroid
carcinoma, prostate-speciﬁc antigen (PSA) and prostate-
speciﬁc membrane antigen (PSMA) for adenocarcinoma
of the prostate, CDX2 and cytokeratin 20 for adenocar-
cinoma of the gastrointestinal tract, and PAX-8, PAX-2,
and estrogen receptor (ER) for serous papillary carci-
noma of the ovary or peritoneum.9 Several markers for
carcinoma of the breast also have use, including estrogen
receptor, progesterone receptor, gross cystic disease
ﬂuid protein (GCDFP)-15, and mammaglobin. It should
be noted that a relatively new marker for breast and
bladder cancers, GATA-3, is expressed in more than half
of mesotheliomas and therefore has limited or no use in
this regard.10
Table 2. Immunohistochemistry of Epithelioid Malignant
Mesothelioma
Mesothelial Markers
Markers Sensitivity
Speciﬁcity
versus Lung
Adenocarcinoma
Calretinin > 90% 90%–95%
CK5/6 75%–100% 80%–90%
WT1 70%–95% w100%
D2-40 90%–100% 85%
Adenocarcinoma (Positive Epithelial Markers)
Markers Sensitivity
Speciﬁcity versus
Malignant
Mesothelioma
MOC31 95%–100% 85%–98%
BerEP4 95%–100% 74%–87%
BG8 (Lewis Y) 90%–100% 93%–97%
B72.3 25%–85% > 95%
Monoclonal
carcinoembryonic
antigen
80%–100% > 95%
Organ Speciﬁc – Lung
Markers Sensitivity
Speciﬁcity versus
Malignant
Mesothelioma
TTF1 (8G7G3/1) w80% High
Napsin A w80% High
Organ Speciﬁc – Breast
Markers Sensitivity
Speciﬁcity versus
Malignant
Mesothelioma
Estrogen receptor a NA NA
Progesterone
receptor
NA NA
GCDFP15 30%–40% High
Mammaglobin 50%–85% High
Organ Speciﬁc – Renal
Markers Sensitivity
Speciﬁcity versus
Malignant
Mesothelioma
PAX8 70%–100% Unknown
PAX2 80% Unknown
RCC  85% 75%–90%
CD15 (LeuM1) 60%a High
Adapted with permission from Travis et al.1
aVariable by subtype.
CEAm, monoclonal carcinoembryonic antigen; NA, not available.
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morphology may somewhat resemble squamous cell
carcinoma. In this situation, p40 (or p63) immunohisto-
chemistry is useful, because nuclear staining with theseantibodies is strongly and diffusely positive in squamous
cell carcinoma but not in mesothelioma. Staining for
cytokeratins 5/6 is of no use in this differential diagnosis
because both epithelioid mesothelioma and squamous
cell carcinoma stain strongly positive for this marker.11
A broad spectrum immunohistochemical stain for
cytokeratins also has some use, because lack of staining
of an epithelioid neoplasm involving the pleura with this
marker would raise a different set of differential diag-
nostic considerations, including large cell lymphoma,
malignant melanoma, epithelioid hemangioendothe-
lioma, and epithelioid angiosarcoma.9 Useful hemato-
poietic markers include CD45 and CD20. Similarly,
HMB45, melan A, and SOX10 are useful markers for
melanoma. Endothelial markers such as CD31, CD34, v-
ets avian erythroblastosis virus E26 (ERG), and Fli-1
have use in the diagnosis of rare cases of angiosarcoma
or epithelioid hemangioendothelioma involving the
pleura (see below).9 As a precaution, it should be noted
that these latter two endothelial-derived malignancies
may show some staining for cytokeratins, although it is
usually focal. In addition, immunostaining for broad
spectrum cytokeratins may be helpful in the diagnosis of
desmoplastic DMM, especially for the identiﬁcation of
invasion of adipose tissue or lung parenchyma by
keratin-positive spindle cells.
Immunohistochemistry has a more limited role in the
separation of sarcomatoid malignant mesothelioma from
other sarcomas and sarcomatoid malignancies that
involve the pleura (Table 2). The vast majority of sar-
comatoid mesotheliomas stain positive for broad-
spectrum anticytokeratin antibodies, whereas most soft
tissue sarcomas do not.12 Keratin stains can be negative
in approximately 5% of sarcomatoid mesotheliomas and
10% of tumors with heterologous elements.12,13 A useful
role of keratin staining in the setting of sarcomatoid
DMM is in revealing the invasion of tumor cells into fat.
Calretinin is seen in only about 30% of cases, including
those with heterologous elements.12,13 Mesothelial
markers useful for the diagnosis of epithelioid meso-
thelioma are rather insensitive for sarcomatoid meso-
theliomas, the majority of which are negative for
calretinin, cytokeratin 5/6, and WT-1. These tumors are
more often positive for D2-40. Sarcomatoid mesotheli-
omas are typically positive for vimentin and may also
show positivity for S-100, actin, or desmin, but these
markers have no diagnostic speciﬁcity.
One must be particularly careful to distinguish sar-
comatoid mesothelioma from other sarcomatoid malig-
nancies involving the pleura that may be positive for
cytokeratins. Monophasic synovial sarcomas may be
identiﬁed by demonstrating the SYT–SSX fusion protein
by ﬂuorescence in situ hybridization (FISH). Sarcomatoid
carcinomas may be positive for TTF-1, Napsin A, or
Table 3. Reactive Atypical Mesothelial Hyperplasia versus Epithelioid Malignant Mesothelioma
Histological Features Atypical Mesothelial Hyperplasia Malignant Mesothelioma
Major criteria
Stromal invasion Absent Present (the deeper the more deﬁnitive)
Cellularity Conﬁned to the pleural surface Dense, with stromal reaction
Papillae Simple, lined by single-cell layer Complex, with cellular stratiﬁcation
Growth pattern Surface growth Expansile nodules, complex and disorganized pattern
Zonation Process becomes less cellular towards chest
wall
No zonation of process, often more cellular away from
effusion
Vascularity Capillaries are perpendicular to the surface Irregular and haphazard
Minor criteria
Cytological atypia Conﬁned to areas of organizing effusion Present in any area, but many cells are deceptively bland
and relatively monotonous
Necrosis Rare (necrosis may be within pleural
exudates)
Necrosis of tumor area is usually a sign of malignancy
Mitoses Mitoses may be plentiful Many mesotheliomas show few mitoses (but atypical
mitoses favor malignancy)
Adapted with permission from Travis et al.1
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squamous differentiation is present. Another differential
diagnosis that occasionally arises is separation of sar-
comatoid mesothelioma from solitary (localized) ﬁbrous
tumors of the pleura. The latter stain positive for CD34
and bcl-2, and are usually keratin-negative. As described
below, more recently, these tumors have been shown
to be positive for STAT6 (Table 2).14 Separation of sar-
comatoid DMM and solitary ﬁbrous tumor (SFT) is
usually not difﬁcult because most of the latter are
benign. However, it can be challenging with malignant
SFTs where CD34 expression is lost. In this setting, the
gross appearance can be helpful because DMMs typically
cause diffuse pleural thickening, and SFTs are localized
masses, even when malignant. In addition, most DMMs
are positive for cytokeratin stains while SFTs are typi-
cally negative, and STAT6 is usually positive in SFTs and
negative in DMMs.
Separation of Benign from Malignant
Mesothelial Proliferations
Since 2004, the criteria for distinguishing malignant
DMM from reactive mesothelial proliferations have been
reﬁned.15–19 Morphologic criteria for distinguishing
epithelioid malignant DMMs from reactive mesothelial
hyperplasia and organizing pleuritis (or chronic ﬁbrous
pleuritis) are recognized (Table 3).1,18,20 However, in
many cases, application of these criteria are challenging
for a variety of reasons, including the size of the biopsy
specimen, sampling problems, entrapment of mesothe-
lial cells, and tangential cuts.1,18
Morphology. The separation of benign from malignant
mesothelial proliferations remains a difﬁcult problem.
The new classiﬁcation reemphasizes the idea that un-
less one has overt tumor fragments, invasion of thestroma remains the single best criterion for diagnosing
malignant mesothelioma. Pan-keratin stains can be
extremely helpful in showing subtle invasion that may
not be readily apparent on hematoxylin–eosin-stained
specimens.
Zonation—increased cellularity immediately under
the pleural effusion (sometimes associated with mar-
ked cytologic atypia right under the effusion) and a pro-
gressive decrease in cellularity away from the effusion—is
a useful marker of a benign process (Fig. 1A); mesotheli-
omas, on the other hand, may show greater cellularity
away from the effusion or homogeneously high cellularity
throughout a greatly thickened pleura. Layering of
mesothelial cells interspersed with collagen immediately
adjacent to the pleural space is also a sign of a benign
reaction; the layering represents repeated effusions that
organize, leaving a mesothelial layer and underlying
ﬁbrosis (Fig. 1A).
Because invasion is by far the best marker of meso-
thelial malignancy, mesothelial proliferations conﬁned to
the pleural surface represent an ongoing problem
without a good solution. Heaped up masses of meso-
thelial cells are suggestive of malignancy, but this is not
always true; conversely, simple papillae with a single
layer of covering cells are more typical of a benign
reaction—but again, this is not always true. Judging from
cases that have both a surface proliferation and under-
lying invasive mesothelioma, many surface proliferations
are simply extensions of an invasive tumor onto the
pleural surface, and p16 FISH is potentially useful in
marking such cases (see below).17 True mesothelioma in
situ presumably exists, but at this point there are no
criteria to allow that diagnosis, and the use of this term
is discouraged.
Desmoplastic mesothelioma versus organizing pleur-
itis presents a somewhat different set of morphologic
Figure 2. Organizing pleuritis. (A) The pleural cavity is on the left, and the chest wall fat (not sampled) would appear on the
right. The biopsy specimen reveals zonation—that is, it is more cellular adjacent to the pleural cavity and less cellular away
from the pleural cavity. In addition, there is layering of mesothelial cells immediately adjacent to the pleural space; this is a
sign of a benign process. This particular example shows fake fat located deep in the pleura near the junction with the chest
wall; note the characteristic pattern of fat-like spaces parallel to the pleura surface (right). (B) Keratin staining of an area of
fake fat from another case. Keratin-positive mesothelial cells run between the spaces (highlighted by arrows), suggesting the
invasion of fat. However, all of the mesothelial cells are aligned parallel to the pleural surface and do not invade down (i.e.,
away from the pleural surface), the diagnostic ﬁnding that would be seen in desmoplastic mesothelioma.
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have a short storiform pattern (“patternless pattern”) of
cells in haphazardly arranged slits between collagen
bundles. Again, invasion of the stroma (usually chest wall
fat) is by far the best criterion of malignancy, and pan-
keratin stains should be used to highlight invasion. As is
true of epithelial mesothelial processes, zonation is also
helpful in making this separation, because desmoplastic
mesotheliomas do not show zonation. The presence of
expansile stromal nodules, areas of frankly sarcomatous
tumor, and bland necrosis all favor desmoplastic meso-
thelioma, but these criteria are not as robust as invasion.
The presence of a focal, clearly malignant, epithelioid
component can also support a diagnosis of malignancy.
A phenomenon that represents a source of confusion
is so-called “fake fat,” an artifact related to traction caused
by obtaining biopsy specimens from densely ﬁbrotic
pleura19 (Fig. 2A and B). Fake fat consists of rounded to
elongated spaces aligned parallel to the pleural surface in
thickened and ﬁbrotic pleura; the spaces are most often
near the junction of the ﬁbrotic pleura with the chest wall
fat. When the spaces are elongated, they are elongated
parallel to the pleural surface. True fat stains for S-100 or
calretinin, whereas the spaces of fake fat stain for neither,
but often contain weakly hematoxyphyllic ﬂocculent
material. All active benign or malignant mesothelial pro-
cesses are pan-keratin–positive, and one of the things that
makes fake fat treacherous is the presence of pan-kera-
tin–positive, benign reactive mesothelial cells coursing
between the spaces (Fig. 2B); at ﬁrst glance, there appears
to be invasion of fat. However, in desmoplastic meso-
theliomas, invasive pan-keratin–positive cells always
spread downward at an angle to the pleural surface into
the underlying true fat or chest wall muscle, whereas with
fake fat the keratin-positive cells are always located in thedensely ﬁbrotic pleura and run parallel to the pleural
surface (Fig. 2B).
Immunohistochemical Findings. A variety of immu-
nohistochemical stains have been proposed as markers
of either benign mesothelial processes (desmin) or me-
sothelioma (e.g., p53, EMA, GLUT-1, and IMP-3). None of
these markers has an established molecular or metabolic
basis, all of them show overlap between benign and
malignant, and at best they provide statistical differences
in large series but are of little value in individual cases.18
Even GLUT-1, which is linked to cellular metabolic ac-
tivity (essentially the same process that drives positron
emission tomography scans), stains some benign re-
actions. Another problem is that red blood cells stain
intensely for GLUT-1, making interpretation difﬁcult.
Recent analysis of data regarding immunohistochemistry
for EMA, GLUT-1, and IMP-3 suggests these markers are
not useful in this setting.16 The molecular markers of p16
FISH and BRCA1-associated protein 1 (BAP1) immuno-
histochemistry have shown promise in helping to
distinguish benign from malignant mesothelial pro-
liferations, as explained below.
Sarcomatoid Mesothelioma with and without
Heterologous Elements
Since 2004, several comprehensive studies of sarco-
matoid DMM have better deﬁned the frequency and
spectrum of various histologic and immunohistochemical
features, including heterologous elements.12,13 In one
study of 326 cases, histologic review showed that
44% were conventional sarcomatoid tumors, desmo-
plastic foci were seen in 34% of cases, but 21% of
sarcomatoid mesotheliomas were classiﬁed as desmo-
plastic mesothelioma, 2% had osteosarcomatous and or
Figure 3. Diffuse malignant mesothelioma, sarcomatoid type with heterologous elements. (A) Malignant bone and cartilage
represent osteosarcomatous and chrondrosarcomatous differentiation in this malignant mesothelioma. (B) Rhabdomyo-
sarcomatous differentiation in this mesothelioma shows highly atypical tumor cell cytology with prominent epithelioid
cytoplasm, suggesting rhabdomyoblasts. (C) Immunohistochemistry of the tumor in part B shows positive staining for myo-
genin, conﬁrming rhabdomyosarcomatous differentiation. (B and C, Reprinted from Travis et al.1, with permission from
Dr. William D. Travis.)
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lymphohistiocytoid pattern.12 When heterologous ele-
ments are present, they most often consist of osteo-
sarcomatous elements followed by a mixture of
chondrosarcoma and osteosarcoma (Fig. 3A), rhabdo-
myosarcoma, and chondrosarcoma only.13 In some
tumors with rhabdomyosarcomatous differentiation, the
morphology may only be suggestive and the diagnosis
requires conﬁrmation with myogenin (Fig. 3B and C) or
MyoD1,1,13 or the speciﬁc PAX3/7–FOXO1 fusion by
FISH.22 These tumors need to be distinguished from pri-
mary and secondary pleural sarcomas, including osteo-
sarcomas and chondrosarcomas, and carcinosarcomas of
the lung. In the setting of a tumor showing diffuse pleural
thickeningwith heterologous elements, even if the keratin
stain is negative, by convention the diagnosis of malignant
mesothelioma is preferred over osteosarcoma, chon-
drosarcoma, or rhabdomyosarcoma.1,13
As described above, sarcomatoid DMMs can rarely be
keratin-negative, and most are negative for mesothelial
markers, such as calretinin. The diagnosis of malignant
mesothelioma can be made in the absence of keratin
and calretinin expression if the morphologic, clinical,
and radiologic features are otherwise consistent withmesothelioma. In particular, there should be diffuse
pleural thickening with absence of an intrapulmonary
mass or a history of soft tissue sarcoma.
Well-Differentiated Papillary Mesothelioma
Several articles have better deﬁned the pathologic
and clinical features of pleural WDPMs.23,24 While
WDPMs are more frequently found in the peritoneal
cavity, these tumors have similar clinical and pathologic
features. WDPM represents a distinct mesothelial tumor
characterized histologically by superﬁcial spreading of
papillary formations with broad ﬁbrovascular cores,
often with myxoid stroma (Fig. 4A and B). They are lined
by bland, ﬂattened, or epithelioid mesothelial cells,
without or with limited invasion of the submesothelial
layer. Invasion can consist of invasion of stalks of
papillae by bland-appearing cells or cytologically higher
grade solid foci. The major challenge in diagnosis is
separation from papillary forms of conventional DMM.
This may be difﬁcult in small biopsy specimens. Solid
foci of tumors favor DMM. Correlation with radiologic
and operative ﬁndings is important. WDPMs typically
form small translucent nodules in contrast to DMMs,
which typically have solid nodules or diffuse pleural
Figure 5. Utility of p16 ﬂuorescence in situ hybridization
(FISH) to separate benign from malignant mesothelial pro-
liferations. This patient was thought to have a mesothelioma,
but the biopsy specimen was equivocal with vague stromal
nodules (marked with an asterisk), suggestive of a desmo-
plastic mesothelioma. FISH (inset) reveals a complete loss of
red p16 signals, indicating that the process is in fact malig-
nant. Green signals represent centromere 9.
Figure 4. Well differentiated papillary mesothelioma. (A) This tumor consists of exophytic surface growth on the pleural
surface, consisting of papillary fronds with broad ﬁbrovascular cores. No downward invasive growth was seen. (Reprinted
from Travis et al.1, with permission from Dr. Francoise Galateau-Salle.) (B) These papillae have broad ﬁbrovascular cores with
a myxoid stroma. The surface of the papillae is lined by cuboidal mesothelial cells with bland cytology.
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indolent clinical outcome, and in most cases are clini-
cally benign if completely resected.23 Whether WDPMs
can progress to DMMs is uncertain. WDPMs with inva-
sive foci conﬁned to the stalk are prone to recurrences
but are rarely fatal.24
Pleural Malignant Mesothelioma:
Promising Advances
Over the past decade, several observations have been
made in mesothelioma pathology and genetics that have
promise to signiﬁcantly impact clinical practice. These are
now the subject of further investigation to determine if
they can be validated. These include histologic grading,
use of BAP1 immunohistochemistry and p16 FISH in sep-
aration of DMM from reactive mesothelial proliferations,
use of STAT6 immunohistochemistry for diagnosis of
solitary ﬁbrous tumor, and FISH for theWWTR1/CAMTA1
fusion for diagnosis of epithelioid hemangioendothelioma
and b-catenin immunohistochemistry25 and CTNNB1
mutation26 for the identiﬁcation of sporadic, desmoid-
type ﬁbromatosis located in the pleura.
Histologic Grading of Diffuse Malignant
Mesothelioma, Epithelioid Type
Histologic grading is inherently built into the histo-
logic typing of DMM because most studies show that
epithelioid tumors have the best prognosis with
decreased survival for biphasic followed by sarcomatoid
tumors.4,5 Because the prognosis for biphasic and sar-
comatoid DMMs is so poor, it is mainly in the lower grade
epithelioid DMMs that there is an opportunity to show
prognostic signiﬁcance to grading. However, there is no
established histologic grading system for epithelioid
DMMs. A preliminary study proposed a grading system
for pleural DMM using nuclear atypia andmitotic count.27
In this study, nuclear atypia, chromatin pattern, promi-
nence of nucleoli, mitotic count, and atypical mitosescorrelated with poor survival by univariate analysis.
Multivariate analysis showed that nuclear atypia and
mitotic count were independent prognostic factors. These
two factors were used to create a three-tier nuclear grade
score that stratiﬁed patients into three distinct prog-
nostic groups: grade I (n ¼ 107; median overall survival,
28 months), grade II (n ¼ 91; median overall survival, 14
months), and grade III (n¼ 34; median overall survival, 5
months).27 When analyzed with other clinicopathologic
factors, this nuclear grading system was a stronger
discriminator of both overall survival and time to recur-
rence. Unfortunately, there are no other published
studies to date that have attempted to validate this in
pleural mesothelioma. A recent article evaluating peri-
toneal epithelioid mesotheliomas found that a high
mitotic rate was associated with poor overall survival,
although this was only shown by univariate analysis.28
Figure 6. BRCA1-associated protein 1 (BAP1) immunostaining in mesothelioma. These examples of mesotheliomas show the
(A) retention and (B) loss of BAP1 from a tissue microarray. Arrows point out positive stromal cells and lymphocytes that serve
as internal staining controls.
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Molecular Abnormalities
The most common genetic changes in DMM are
inactivation of the tumor suppressor gene NF2; deletion
of the 9p21 locus, which harbors p16INK4A, p14ARF,
MTAP, and p15INK4B; and mutation of BAP1.1 The most
useful potential genetic markers for diagnostic applica-
tions are for p16 FISH and BAP1 immunohistochemistry.
The loss of p16INK4A (also called CDKN2A) can be
detected using FISH.29,30 A number of studies have
shown that p16 loss by FISH is never seen in benign
mesothelial processes, and this approach is therefore
potentially a highly accurate method for separating
benign from malignant mesothelial processes16,29–32
(Fig. 5). The major limitation of p16 detected by
FISH is that the test only shows loss in a proportion of
mesotheliomas, with better results (up to 100% of cases
in some series32) for sarcomatoid mesotheliomas
compared to epithelioid mesotheliomas; failure to ﬁnd
p16 loss by FISH therefore does not make a process
benign. The diagnostic ﬁnding of p16 loss is homozygous
deletion rather than heterozygous.16,29–32
It has been reported that there is a 100% concordance
in p16 FISH results between underlying invasive meso-
thelioma and surface mesothelial proliferations in theFigure 7. Solitary ﬁbrous tumor. (A) This neoplasm consists of
prominent ropy collagen. (B) Immunohistochemistry for STAT6same case,17 so that loss of p16 by FISH is a potentially
useful test when there is radiologic or direct visual evi-
dence of pleural tumor, but biopsy specimens reveal only
a surface proliferation. p16 deletion by FISH has also been
shown to be useful to favor DMM in cytologic specimens
of pleural effusions in the setting of clinical and radiologic
evidence of diffuse pleural thickening.33–35 These result
needs conﬁrmation from additional studies. This is
important because differentiation of mesothelioma from
benign mesothelial reactions may be difﬁcult or even
impossible in cytologic specimens.1 The accuracy of
purely cytologic diagnoses of malignant mesothelioma is
fairly low compared to that of tissue diagnoses.9
Loss of p16 by FISH is also correlated with a poorer
prognosis.36,37 It should be noted that p16 immunohis-
tochemistry does not give the same results and cannot
be substituted for p16 FISH,29 although loss of p16
immunohistochemical staining is also a marker of a
poorer prognosis.36
Thediscoveryof inactivatingmutations in theBAP1gene
in sporadic, and hereditary DMMhas opened up a variety of
novel molecular, clinical, and diagnostic investigations.38,39
BAP1 mutations are found in a substantial proportion of
epithelioid mesotheliomas (roughly 40–60%), and a lesser
proportion of sarcomatoid mesotheliomas (< 20%).40,41spindle cells in a storiform pattern with a stroma showing
shows diffuse strong nuclear staining.
Figure 8. Epithelioid hemangioendothelioma. (A) The pleura is markedly thickened and inﬁltrated by a cellular neoplasm.
There is extensive inﬁltration of parietal pleural fat. (B) The tumor has a hyaline stroma inﬁltrated by cytologically bland
epithelioid cells with some intracytoplasmic lumens (center). (C) CD31 shows diffuse strong staining. (D and E) Fluorescence
in situ hybridization analysis using custom BAC probes shows break-apart signals (arrows in CAMTA1 [D] and WWTR1 [E]). Red,
centromeric; green, telomeric. (D and E, Courtesy of Dr. Cristina Antonescu.)
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< 5%) represent germline mutations, and these patients or
their kindred may also harbor ocular and cutaneous mela-
nomas, renal cell carcinomas, and a variety of other tu-
mors.38,39,42,43 From a diagnostic perspective, this is a
potentially useful marker because there is a reliable
immunohistochemical marker and mutation of the gene
results in loss of nuclear staining (Fig. 4).16,38,44,45
One promising diagnostic application includes the
setting of separating DMMs from reactive mesothelial
proliferations where they may play a role in conjunction
with p16 FISH.16,17,46 Recent studies by Shefﬁeld et al.,16
Hwang et al.,17 and Cigognetti et al.44 suggest that loss ofp16 detected by FISH and the loss of BAP1 (Fig. 6A and B)
detected by immunohistochemistry may be useful in
separating malignant DMM from reactive pleuritis.
Cigognetti et al.44 found BAP1 loss mostly in epithelioid
DMMs rather than sarcomatoid tumors, suggesting that
this feature is most useful in the differential diagnosis of
epithelioid mesothelial proliferations. They also pre-
sented data suggesting that BAP1 loss may be useful in
cytologic specimens to favor the diagnosis of mesotheli-
oma.44 Shefﬁeld et al.16 combined BAP1/p16 FISH results
and found this to be a highly speciﬁc method of diag-
nosing malignant DMMs in the setting of problem cases in
the distinction of benign versus malignant mesothelial
Figure 9. Desmoid tumor. (A) This tumor consists of bland spindle cells with sharply tapered nuclei growing within a ﬁbrous
stroma. (B) Immunohistochemistry for b-catenin shows positive nuclear staining.
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demonstrate. This combination was also 58% sensitive
for detecting malignancy.16 Thus far, BAP1 loss has not
been seen in benign mesothelial reactions, and BAP1
staining is a potentially useful approach to separating
benign and malignant mesothelial processes16—but this
issue needs further conﬁrmation. As is true of p16 FISH,
not all mesotheliomas show BAP1 loss, so failure to ﬁnd
loss of BAP1 does not make a mesothelial process
benign.16 In addition, because the loss of BAP1 by
immunohistochemistry and deletion of p16 detected by
FISH are not only seen in mesothelioma but also in other
tumors, it remains essential to apply standard criteria for
the diagnosis of mesothelioma before using these tests.46STAT6 Immunohistochemical Marker for Solitary
Fibrous Tumor
Another useful discovery from a whole-exome
sequencing study was that the NAB2–STAT6 fusion is
characteristic of solitary ﬁbrous tumor.14,47 SFTs are
rare mesenchymal tumors that have distinctive histo-
logic features (Fig. 7A), allowing for deﬁnitive diagnosis
without the need for special stains. However, in some
cases, the diagnosis is challenging, particularly in small
biopsy specimens or when characteristic histologic pat-
terns are not readily apparent. Using whole-exome
sequencing, identiﬁcation of the NAB2–STAT6 fusion in
SFT47,48 led to the development of an antibody to STAT6,
which shows nuclear reactivity (Fig. 7B) and is a useful
diagnostic immunohistochemical marker.14 However, it
is not a speciﬁc marker, because it is also expressed in a
small percentage of desmoid tumors and unclassiﬁed
sarcomas that potentially could be confused with SFT.49WWTR1–CAMTA1 Fusion as a Marker for
Epithelioid Hemangioendothelioma
Another useful genetic discovery is the ﬁnding that
most epithelioid hemangioendotheliomas have a speciﬁc
translocation (i.e., [1;3][p36;q2325]), which results in
WWTR1–CAMTA1 gene fusion.50–52 A small percentage ofthese tumors may have a YAP1–TFE3 fusion.53 Epithelioid
hemangioendothelioma is a low- to intermediate-grade
malignant vascular tumor that can present in the pleura
(Fig. 8A–C). Patients with tumors that present primarily
as pleural masses have a signiﬁcantly poorer prognosis
than those that present as lung tumors.54 Histologically, it
is composed of cords, strands, or solid nests of epithelioid
endothelial cells in a myxohyaline stroma.54,55 They may
be low- or intermediate-grade, with the latter distin-
guished by the presence of necrosis, increased mitotic
activity (mean, 2/2 mm2), and greater nuclear atypia.54
Epithelioid hemangioendotheliomas are distinguished
from the high-grade and clinically more aggressive
epithelioid angiosarcomas, which are more likely to show
prominent capillary-like vasoformative elements, blood
lakes, papillary growth, and prominent nucleoli.54 In
addition, epithelioid angiosarcomas typically lack
WWTR1–CAMTA1 fusions.54 Immunohistochemistry for
the vascular markers CD31 (Fig. 8C), CD34, ERG, and FLI1
can be useful in conﬁrming the diagnosis. Focal cytoker-
atin expression is present in 25% to 30% of cases.54 In
some difﬁcult cases, particularly in small biopsy speci-
mens, FISH for the WWTR1–CAMTA1 fusion (Fig. 8D and
E) can be a valuable diagnostic tool.54
CTNNB1 Mutation and b-Catenin
Immunohistochemistry in Desmoid-Type
Fibromatosis
Desmoid-type ﬁbromatosis is a locally aggressive
myoﬁbroblastic neoplasm that can present in the pleura.
These tumors are poorly deﬁned, highly inﬁltrative masses
that often invade soft tissues of the chest wall. Histologi-
cally, the tumors consist of cytologically uniform ﬁbro-
blastic/myoﬁbroblastic cells arranged in long fascicles
within a ﬁbrillary or hyalinized ﬁbrous stroma (Fig. 9A).
Tumor cells are ovoid or spindle-shaped. These tumors can
express smoothmuscle actin ormuscle-speciﬁc actin. They
can express nuclearb-catenin by immunohistochemistry in
up to 75% of cases (Fig. 9B).25,56 Sporadic desmoid-type
ﬁbromatosis have been shown to have catenin-associated
protein b1 (CTNNB1) gene mutations in about 85% of
February 2016 2015 WHO Classiﬁcation of Tumors of the Pleura 153cases.26 It has been suggested that CTNNB1mutations may
be prognostic for local recurrence,57 although this remains
to be proven.26Summary
In summary, while the essential structure of the 2015
WHO Classiﬁcation of Pleural Tumors is similar to that
published in 2004, we review in this article some of the
exciting genetic advances that have led to improved
diagnostic methods.Supplementary Data
Note: To access the supplementary material accompa-
nying this article, visit the online version of the Journal of
Thoracic Oncology at www.jto.org and at http://dx.doi.
org/10.1016/j.jtho.2015.11.005.
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